Intellia Therapeutics Inc (NASDAQ: NTLA) is 3.09% higher on its value in year-to-date trading and has touched a low of $11.34 and a high of $34.87 in the current 52-week trading range. The question becomes, what are the chances the stock will continue to grow shareholders’ wealth in the market. Here’s what analysts think will happen to its price in the coming time. The NTLA stock was last observed hovering at around $12.47 in the last trading session, with the day’s loss setting it -0.45%.
Currently trading at $12.02, the stock is -4.23% and -14.41% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 1.89 million and changing -3.61% at the moment leaves the stock -41.98% off its SMA200. NTLA registered -60.03% loss for a year compared to 6-month loss of -48.08%. The firm has a 50-day simple moving average (SMA 50) of $14.1216 and a 200-day simple moving average (SMA200) of $20.793175.
The stock witnessed a -18.34% gain in the last 1 month and extending the period to 3 months gives it a -32.81%, and is 3.09% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 5.63% over the week and 5.57% over the month.
Intellia Therapeutics Inc (NTLA) has around 526 employees, a market worth around $1.22B and $43.09M in sales. Profit margin for the company is -1212.19%. Distance from 52-week low is 6.00% and -65.53% from its 52-week high. The company has generated returns on investments over the last 12 months (-49.98%).
The EPS is expected to grow by 2.16% this year
419.0 institutions hold shares in Intellia Therapeutics Inc (NTLA), with institutional investors hold 92.61% of the company’s shares. The shares outstanding are 101.80M, and float is at 100.10M with Short Float at 19.79%. Institutions hold 91.50% of the Float.
The top institutional shareholder in the company is ARK INVESTMENT MANAGEMENT LLC with over 11.6 million shares valued at $259.51 million. The investor’s holdings represent 12.1419 of the NTLA Shares outstanding. As of 2024-06-30, the second largest holder is BLACKROCK INC. with 9.6 million shares valued at $214.79 million to account for 10.0496 of the shares outstanding. The other top investors are VANGUARD GROUP INC which holds 9.1 million shares representing 9.5287 and valued at over $203.66 million, while DEEP TRACK CAPITAL, LP holds 5.0261 of the shares totaling 4.8 million with a market value of $107.42 million.
Intellia Therapeutics Inc (NTLA) Insider Activity
The most recent transaction is an insider sale by Dube Michael P, the company’s VP, Chief Accounting Officer. SEC filings show that Dube Michael P sold 1,372 shares of the company’s common stock on Jan 03 ’25 at a price of $12.18 per share for a total of $16711.0. Following the sale, the insider now owns 45640.0 shares.
Intellia Therapeutics Inc disclosed in a document filed with the SEC on Jan 03 ’25 that BASTA JAMES (EVP, General Counsel) sold a total of 7,074 shares of the company’s common stock. The trade occurred on Jan 03 ’25 and was made at $12.18 per share for $86161.0. Following the transaction, the insider now directly holds 74497.0 shares of the NTLA stock.
Still, SEC filings show that on Jan 03 ’25, Lebwohl David (EVP, Chief Medical Officer) disposed off 9,557 shares at an average price of $12.18 for $0.12 million. The insider now directly holds 87,666 shares of Intellia Therapeutics Inc (NTLA).
